According to Future Market Insights research, during the projected period, the Global point-of-care diagnostics market is expected to grow at a CAGR of 6.8%. The market value is projected to increase from US$ 38.7 Billion in 2023 to US$ 74.8 Billion by 2033. The point-of-care diagnostics market was valued at US$ 36.6 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 5.8% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 36.6 Billion |
| Market Value 2023 | US$ 38.7 Billion |
| Market Value 2033 | US$ 74.8 Billion |
| CAGR 2023 to 2033 | 6.8% |
| Share of Top 5 Countries | 56.5% |
| Key Players | The key players in the Global Point-of-Care Diagnostics Market Are F. Hoffmann-La Roche Ltd; Becton Dickinson & Company; Cepheid (Danaher);Siemens Healthineers; Abbott; Diasorin S.p.a.; Thermo Fisher Scientific Inc.; Qiagen; BIOMÉRIEUX; Hologic Inc.; Bio Rad Laboratories; Quidel Corporation; EKF Diagnostics; SEKISUI Diagnostics; DiaSys-Diagnostic Systems GmbH; InBios International; Inc.; Jiangsu Mole Bioscience Co.; Ltd.; ACON Laboratories; Inc.; Visby Medical; Inc.; UNIMA; INC. |
Point-of-Care testing (POCT) refers to medical diagnostic testing that is performed near the patient, usually at the bedside or in a doctor's office, rather than in a central laboratory. The goal of POCT is to provide rapid and accurate diagnostic results that can guide clinical decision-making in real-time.
The world is seeing rapid advancements in a wide range of digital health technologies, including portable and ingestible devices; mobile health apps; artificial intelligence (AI); robots used in healthcare; 3D organ printing; block chain; telemedicine; machine learning; genome research; drones; augmented and virtual reality; and electronic records. However, the market is also shifting to digitalization, so the influx of digital health technologies is a prominent driver for point-of-care diagnostic market.
Accelerating the adoption of proven digital health technologies and advancing their embedding into routine care operations has the potential to revolutionize human health by boosting efficacy, driving costs down, and increasing access to and capacity for care delivery.
New product launches and approvals such as Lab-on-a-chip technology is one of the main drivers of POCT.
Overall, the increasing adoption of latest technologies and new product launches and approvals is likely to boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the global point-of-care diagnostics market grew at a CAGR of 6.2% between 2012 to 2022. Global point-of-care diagnostics market contributes 40.0% revenue share to the global in-vitro diagnostics market valued at US$ 91.2 Billion in 2022.
The increasing prevalence of Infectious diseases has resulted in higher uptake of POC diagnostic options such as Glucose and Hb1Ac testing. Because of their easy availability and rapid diagnosis, point-of-care diagnostics are typically the first form of testing recommended worldwide.
A significant advance has been made in the effort to identify SARS-CoV-2 coronavirus patients with the addition of saliva samples for the purpose of coronavirus identification. Governments concentrated on raising knowledge about COVID-19 testing during the COVID-19 epidemic to ensure an early identification of the illness. As a result of such initiatives, people become more knowledgeable of Point-of-Care testing for the diagnosis of coronavirus.
Creating awareness about diseases is an essential aspect of early detection and screening. If the public has a general understanding of diseases and symptoms, action plans can be better implemented. On the other hand, if there is a lack of awareness, it stops people from taking preventive measures or availing treatments.
Considering this, FMI expects the global market to grow at a CAGR of 6.8% through the forecasted years.
There is a lack of expansion of biotechnology & pharmaceutical Industries regarding point-of-care diagnostics. Biopharmaceuticals are one of modern science's most technically advanced and exquisite achievements. Pharmaceutical companies are putting in a lot of effort to produce medications and lifesaving vaccines and biologicals for the entire world. When the pharmaceutical sector employs biotechnological advancements and advanced processes, the result is better and faster drug delivery. Biotechnology has aided the pharmaceutical sector in the correct manufacturing of vaccines and medications.
The pharmaceutical sector intends to establish products that support the treatment of various diseases. This may result in pharma companies manufacturing point-of-Care (POC) devices.
While greater investment for innovative products is required for the growth of the market, the healthcare infrastructure can have a substantial impact on market expansion. Most healthcare authorities have recently committed increased financing for the development and enhancement of their healthcare infrastructure as a result of the COVID-19 pandemic. The development of Point-of-Care diagnostics kits and their production need more investment.
Overall, healthcare infrastructure for POCT is complex and evolving, and it is important that companies stay abreast of regulatory changes and work closely with regulators to ensure compliance. However, regulatory initiatives that promote safe and effective pain management can create growth opportunities for the POCT market, especially for companies that offer innovative solutions.
Increased testing of point-of-care diagnosis in patients will pave the way for new technology and treatment options, ultimately leading more improvement in healthcare infrastructure and growth in number of manufacturing facilities.
Principal Consultant
Point-of-Care tests in some therapy areas have become more accurate (e.g., glucose testing). Overall, POC tests and rapid tests tend to remain less accurate compared to tests run in a laboratory. Accuracy is essential in medical testing, because an incorrect diagnosis can lead to inappropriate treatment, which can have serious consequences for patients. Inaccurate POC results can lead to false positives or false negatives, which can result in unnecessary treatment or missed diagnosis, respectively.
Inaccurate POCT results can also lead to mistrust in the technology, which can impact the adoption and utilization of POCT products. Healthcare providers may be hesitant to rely on POCT if they have concerns about its accuracy and reliability.
The cost of tests and a lack of trust in POC/ rapid testing are major concerns around the globe. The cost of point-of-care kits or devices is very high as compared to laboratory tests, which is compounded by the lower level of accuracy offered by the former.
Due to financial constraints, academic research laboratories are often unable to purchase expensive equipment. The overall cost of these instruments increases as a result of maintenance costs and other indirect expenses. Thus, the higher cost associated with the equipment and other factors causing unaffordability for the laboratories might hamper the market growth.
These factors are expected to hamper revenue growth of the global market over the forecast period.
USA dominated the global market in 2022 and is further expected to register growth rate at CAGR of 6.8%.
Diagnostic techniques, such as rapid testing or POCT like COVID-19 testing, glucose testing, and allergy tests, etc., has seen a high rate of patient acceptance as a result of the high prevalence. Awareness campaigns and strategic conferences with focus on point-of-care technologies for healthcare sector, has been undertaken by various associations in USA
In May 2022, American Association for Clinical Chemistry, organized a Point-of-Care testing boot camp for POCT professionals and experts in the lab medicine community.
Why is Germany considered to be a Lucrative Market for Point-of-Care Diagnostics?
The general physicians in primary care settings in Germany highly prefer POCTs as a useful diagnostic tool. There are numerous POCTs available in the German market. In the past few years, due to COVID-19 point-of-care diagnostics has been of tremendous importance as first line of defense for testing purpose.
The safe and successful use of point-of-care diagnostics in Germany is likely to influence other European countries to also opt for this method, ultimately resulting in market expansion.
China is projected to be the most attractive market in the east Asia point-of-care diagnostics and is expected to grow over a significant CAGR of 9.0% over the forecast period.
Point-of-care diagnostics market in China is expected to grow significantly in the coming years due to several factors.
One of the main factors driving the growth of the point-of-care diagnostics market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the POC testing, they are more likely to adapt to the testing method, which is leading to increased demand for testing for Point-of-care diagnostics.
Another factor contributing to the growth of the Chinese market is the increasing availability of advanced medical technologies. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The COVID-19 testing diagnostic segment held the major chunk of about 15.1% in global market by the end of 2022. However, food sensitivity testing is the most lucrative segment over the forecast period due to increase in food allergic cases. Many of allergic reactions require rapid diagnosis that’s where point-of-care diagnostics plays a significant role.
Nasal swabs segment accounted for revenue share of 28.4% in the global market at the end of 2022.
A nasopharyngeal swab, one type of nasal swab, is a test used to look for bacteria or viruses that cause respiratory infections. Your healthcare provider uses a swab to take a small sample of cells from your nasopharynx, the top part of your nose and throat.
Overall, nasal swabs offers a convenient sample type for point-of-care diagnostics for sample withdrawal, making it the largest sample type for this segment.
Handheld POC Monitoring Devices segment accounted for revenue share of 41.3% in the global market at the end of 2022.
Handheld POC monitoring devices can be used to monitor a wide range of medical conditions, such as diabetes, cardiovascular disease, and infectious diseases. For example, a handheld blood glucose meter can be used by patients with diabetes to monitor their blood sugar levels, while a handheld device that measures blood pressure can be used to monitor patients with hypertension.
Overall, Handheld POC Monitoring Devices offers a convenient Product type for Global Point-of-Care diagnostics treating products, making it the largest Product for this segment.
Hospitals held the major chunk of about 27.7% in global market by the end of 2022.
Hospitals offers a convenient end user for POCT market conducting POC tests, making it the dominant end user for this segment. Hospitals segment is set to be highly lucrative in the upcoming years due to ease and access of POCT.
Collaboration are the top strategy being adopted by leading players to expand their product portfolio, their customer base as well as maintain their foothold in the market.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Point-of-care Diagnostics Market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, and GCC Countries |
| Key Segments Covered | Test Type, Sample, Product, End User, Region |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd; Becton Dickinson & Company; Cepheid (Danaher); Siemens Healthineers; Abbott; Diasorin S.p.a.; Thermo Fisher Scientific Inc.; Qiagen; BIOMÉRIEUX; Hologic Inc.; Bio Rad Laboratories; Quidel Corporation; EKF Diagnostics; SEKISUI Diagnostics; DiaSys-Diagnostic Systems GmbH; InBios International, Inc.; Jiangsu Mole Bioscience Co., Ltd.; ACON Laboratories, Inc.; Visby Medical, Inc.; UNIMA, INC. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The growth potential of the market is 6.8% through 2033.
The United States and Germany are projected to emerge as lucrative markets.
Hospitals offer a convenient end user for the POCT market conducting POC tests, making it the dominant end user.
Handheld POC Monitoring Devices accounted for a revenue share of 41.3% in 2022.
Efforts to produce medications and lifesaving vaccines and biologicals for the entire world drive sales.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Value-Added Insights 4.1. Disease Epidemiology, By Indication 4.2. Regulatory Scenario 4.3. Reimbursement Landscape 4.4. Unmet Needs and Opportunities 4.5. Point-of-care Testing (POCT) Compared to a Conventional Testing Procedure 4.6. Challenges and Benefits of POCT 4.7. PESTLE Analysis 4.8. Porter’s Analysis 4.9. Value Chain Analysis 4.10. Parent Market Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.1.3. Global In-vitro Diagnostics Market 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Increasing Treatment Seeking Rate 5.2.3. New Test Type Launches/Approvals 5.2.4. Increasing Diagnosis Rate (%) of Infectious Diseases 5.2.5. Increasing Incidence of Chronic Diseases 5.2.6. Rising Adoption of POC Devices 5.2.7. Government Initiatives to Combat Diseases 5.2.8. Companies Increasingly Spending on R&D and Focus on Innovation 5.2.9. Collaborations and Agreements between Manufacturers 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis - Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. By Test Type 6.1.2. By Product 6.1.3. By Sample 6.1.4. By End User 6.1.5. By Country 6.2. 2022 Market Scenario 7. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Volume Analysis, 2012 to 2022 7.2. Current and Future Market Volume Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Market - Pricing Assessment 8.1. Global Pricing Analysis 8.2. Pricing Assumptions 9. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033 9.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Test Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis by Test Type, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Test Type, 2023 to 2033 10.3.1. Infectious Disease 10.3.1.1. HIV POC Testing 10.3.1.2. Clostridium Difficile POC Testing 10.3.1.3. HBV POC Testing 10.3.1.4. Pneumonia or Streptococcus Associated Infections Testing 10.3.1.5. Respiratory Syncytial Virus (RSV) POC Testing 10.3.1.6. HPV POC 10.3.1.7. Influenza/Flu POC Testing 10.3.1.8. HCV POC Testing 10.3.1.9. MRSA POC Testing 10.3.1.10. TB and Drug-resistant TB POC Testing 10.3.1.11. HSV POC Testing 10.3.2. COVID-19 Testing 10.3.3. Glucose Testing 10.3.4. Hb1Ac Testing 10.3.5. Coagulation Testing 10.3.6. Pregnancy & Fertility Testing 10.3.7. Allergy Tests 10.3.8. Cholesterol & Lipids Tests 10.3.9. Drug of Abuse (DOA) Testing 10.3.10. Food Sensitivity Tests 10.3.11. Metabolism Tests 10.3.12. Vitamin D Tests 10.3.13. Vitamins B Test 10.3.14. Urinary Tract Infection (UTI) Tests 10.3.15. Sexual Health Tests 10.3.16. Water Testing Kits 10.3.17. Alcohol Tests 10.3.18. Others 10.4. Market Attractiveness Analysis by Test Type 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis & Volume Analysis by Product, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) & Volume Analysis and Forecast by Product, 2023 to 2033 11.3.1. Dipstick 11.3.2. Strips & Cards 11.3.3. Cassettes 11.3.4. Handheld POC Monitoring Devices 11.4. Market Attractiveness Analysis by Product 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis by Sample, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Sample, 2023 to 2033 12.3.1. Saliva 12.3.2. Nasal Swabs 12.3.3. Urine 12.3.4. Blood 12.3.5. Plasma 12.3.6. Sweat 12.3.7. Other Fluids 12.4. Market Attractiveness Analysis by Product 13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis by End User, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033 13.3.1. Hospitals 13.3.2. Clinics 13.3.3. Diagnostic Laboratories 13.3.4. Home Care Settings 13.3.5. Non-Government Organization 13.3.6. Government & Federal Agencies 13.3.7. Long-Term Care Centers 13.4. Market Attractiveness Analysis by End User 14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Region, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Region, 2022-2032 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. South Asia 14.3.5. East Asia 14.3.6. Oceania 14.3.7. Middle East & Africa 14.4. Market Attractiveness Analysis by Country 15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Test Type 15.3.3. By Product 15.3.4. By Sample 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Test Type 15.4.3. By Product 15.4.4. By Sample 15.4.5. By End User 15.5. Market Trends 15.6. Key Market Participants- Intensity Mapping 15.7. Drivers & Restraints Impact Analysis 15.8. Country-wise Analysis 15.8.1. USA Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Test Type 15.8.1.2.2. By Product 15.8.1.2.3. By Sample 15.8.1.2.4. By End User 15.8.2. Canada Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Test Type 15.8.2.2.2. By Product 15.8.2.2.3. By Sample 15.8.2.2.4. By End User 16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Argentina 16.3.2. By Test Type 16.3.3. By Product 16.3.4. By Sample 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Test Type 16.4.3. By Product 16.4.4. By Sample 16.4.5. By End User 16.5. Market Trends 16.6. Key Market Participants- Intensity Mapping 16.7. Drivers & Restraints Impact Analysis 16.8. Country-wise Analysis 16.8.1. Brazil Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Test Type 16.8.1.2.2. By Product 16.8.1.2.3. By Sample 16.8.1.2.4. By End User 16.8.2. Mexico Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Test Type 16.8.2.2.2. By Product 16.8.2.2.3. By Sample 16.8.2.2.4. By End User 16.8.3. Argentina Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Test Type 16.8.3.2.2. By Product 16.8.3.2.3. By Sample 16.8.3.2.4. By End User 17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. Italy 17.3.1.3. France 17.3.1.4. UK 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Russia 17.3.2. By Test Type 17.3.3. By Product 17.3.4. By Sample 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Test Type 17.4.3. By Product 17.4.4. By Sample 17.4.5. By End User 17.5. Market Trends 17.6. Key Market Participants- Intensity Mapping 17.7. Drivers & Restraints Impact Analysis 17.8. Country-wise Analysis 17.8.1. Germany Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Test Type 17.8.1.2.2. By Product 17.8.1.2.3. By Sample 17.8.1.2.4. By End User 17.8.2. Italy Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Test Type 17.8.2.2.2. By Product 17.8.2.2.3. By Sample 17.8.2.2.4. By End User 17.8.3. France Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Test Type 17.8.3.2.2. By Product 17.8.3.2.3. By Sample 17.8.3.2.4. By End User 17.8.4. UK Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Test Type 17.8.4.2.2. By Product 17.8.4.2.3. By Sample 17.8.4.2.4. By End User 17.8.5. Spain Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Test Type 17.8.5.2.2. By Product 17.8.5.2.3. By Sample 17.8.5.2.4. By End User 17.8.6. BENELUX Market Analysis 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Test Type 17.8.6.2.2. By Product 17.8.6.2.3. By Sample 17.8.6.2.4. By End User 17.8.7. Russia Market Analysis 17.8.7.1. Introduction 17.8.7.2. Market Analysis and Forecast by Market Taxonomy 17.8.7.2.1. By Test Type 17.8.7.2.2. By Product 17.8.7.2.3. By Sample 17.8.7.2.4. By End User 18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Indonesia 18.3.1.3. Malaysia 18.3.1.4. Thailand 18.3.1.5. Rest of South Asia 18.3.2. By Test Type 18.3.3. By Product 18.3.4. By Sample 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Test Type 18.4.3. By Product 18.4.4. By Sample 18.4.5. By End User 18.5. Market Trends 18.6. Key Market Participants- Intensity Mapping 18.7. Drivers & Restraints Impact Analysis 18.8. Country-wise Analysis 18.8.1. India Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Test Type 18.8.1.2.2. By Product 18.8.1.2.3. By Sample 18.8.1.2.4. By End User 18.8.2. Indonesia Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Test Type 18.8.2.2.2. By Product 18.8.2.2.3. By Sample 18.8.2.2.4. By End User 18.8.3. Malaysia Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Test Type 18.8.3.2.2. By Product 18.8.3.2.3. By Sample 18.8.3.2.4. By End User 18.8.4. Thailand Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Test Type 18.8.4.2.2. By Product 18.8.4.2.3. By Sample 18.8.4.2.4. By End User 19. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. China 19.3.1.2. Japan 19.3.1.3. South Korea 19.3.2. By Test Type 19.3.3. By Product 19.3.4. By Sample 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Test Type 19.4.3. By Product 19.4.4. By Sample 19.4.5. By End User 19.5. Market Trends 19.6. Key Market Participants- Intensity Mapping 19.7. Drivers & Restraints Impact Analysis 19.8. Country-wise Analysis 19.8.1. China Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Test Type 19.8.1.2.2. By Product 19.8.1.2.3. By Sample 19.8.1.2.4. By End User 19.8.2. Japan Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Test Type 19.8.2.2.2. By Product 19.8.2.2.3. By Sample 19.8.2.2.4. By End User 19.8.3. South Korea Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Test Type 19.8.3.2.2. By Product 19.8.3.2.3. By Sample 19.8.3.2.4. By End User 20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Test Type 20.3.3. By Product 20.3.4. By Sample 20.3.5. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Test Type 20.4.3. By Product 20.4.4. By Sample 20.4.5. By End User 20.5. Market Trends 20.6. Key Market Participants- Intensity Mapping 20.7. Drivers & Restraints Impact Analysis 20.8. Country-wise Analysis 20.8.1. Australia Market Analysis 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Test Type 20.8.1.2.2. By Product 20.8.1.2.3. By Sample 20.8.1.2.4. By End User 20.8.2. New Zealand Market Analysis 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Test Type 20.8.2.2.2. By Product 20.8.2.2.3. By Sample 20.8.2.2.4. By End User 21. Middle East & Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022 21.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. GCC Country 21.3.1.2. Türkiye 21.3.1.3. South Africa 21.3.1.4. Rest of MEA 21.3.2. By Test Type 21.3.3. By Product 21.3.4. By Sample 21.3.5. By End User 21.4. Market Attractiveness Analysis 21.4.1. By Country 21.4.2. By Test Type 21.4.3. By Product 21.4.4. By Sample 21.4.5. By End User 21.5. Market Trends 21.6. Key Market Participants- Intensity Mapping 21.7. Drivers & Restraints Impact Analysis 21.8. Country-wise Analysis 21.8.1. GCC Country Market Analysis 21.8.1.1. Introduction 21.8.1.2. Market Analysis and Forecast by Market Taxonomy 21.8.1.2.1. By Test Type 21.8.1.2.2. By Product 21.8.1.2.3. By Sample 21.8.1.2.4. By End User 21.8.2. Türkiye Market Analysis 21.8.2.1. Introduction 21.8.2.2. Market Analysis and Forecast by Market Taxonomy 21.8.2.2.1. By Test Type 21.8.2.2.2. By Product 21.8.2.2.3. By Sample 21.8.2.2.4. By End User 21.8.3. South Africa Market Analysis 21.8.3.1. Introduction 21.8.3.2. Market Analysis and Forecast by Market Taxonomy 21.8.3.2.1. By Test Type 21.8.3.2.2. By Product 21.8.3.2.3. By Sample 21.8.3.2.4. By End User 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players (%) 22.3. Market Concentration 22.4. Market Presence Analysis 23. Competition Analysis 23.1. Competition Dashboard 23.2. Key Development Analysis 23.3. Branding and Promotional Strategies, By Key Players 23.4. Competition Deep Dive 23.4.1. F. Hoffmann-La Roche Ltd 23.4.1.1. Overview 23.4.1.2. Product Portfolio 23.4.1.3. Key Financials 23.4.1.4. SWOT Analysis 23.4.1.5. Key Developments 23.4.1.6. Sales Footprint 23.4.1.7. Strategy Overview 23.4.1.7.1. Marketing Strategy 23.4.1.7.2. Product Strategy 23.4.1.7.3. Channel Strategy 23.4.2. Becton Dickinson & Company 23.4.2.1. Overview 23.4.2.2. Product Portfolio 23.4.2.3. Key Financials 23.4.2.4. SWOT Analysis 23.4.2.5. Key Developments 23.4.2.6. Sales Footprint 23.4.2.7. Strategy Overview 23.4.2.7.1. Marketing Strategy 23.4.2.7.2. Product Strategy 23.4.2.7.3. Channel Strategy 23.4.3. Cepheid (Danaher) 23.4.3.1. Overview 23.4.3.2. Product Portfolio 23.4.3.3. Key Financials 23.4.3.4. SWOT Analysis 23.4.3.5. Key Developments 23.4.3.6. Sales Footprint 23.4.3.7. Strategy Overview 23.4.3.7.1. Marketing Strategy 23.4.3.7.2. Product Strategy 23.4.3.7.3. Channel Strategy 23.4.4. Siemens Healthineers 23.4.4.1. Overview 23.4.4.2. Product Portfolio 23.4.4.3. Key Financials 23.4.4.4. SWOT Analysis 23.4.4.5. Key Developments 23.4.4.6. Sales Footprint 23.4.4.7. Strategy Overview 23.4.4.7.1. Marketing Strategy 23.4.4.7.2. Product Strategy 23.4.4.7.3. Channel Strategy 23.4.5. Abbott 23.4.5.1. Overview 23.4.5.2. Product Portfolio 23.4.5.3. Key Financials 23.4.5.4. SWOT Analysis 23.4.5.5. Key Developments 23.4.5.6. Sales Footprint 23.4.5.7. Strategy Overview 23.4.5.7.1. Marketing Strategy 23.4.5.7.2. Product Strategy 23.4.5.7.3. Channel Strategy 23.4.6. Diasorin S.p.a. 23.4.6.1. Overview 23.4.6.2. Product Portfolio 23.4.6.3. Key Financials 23.4.6.4. SWOT Analysis 23.4.6.5. Key Developments 23.4.6.6. Sales Footprint 23.4.6.7. Strategy Overview 23.4.6.7.1. Marketing Strategy 23.4.6.7.2. Product Strategy 23.4.6.7.3. Channel Strategy 23.4.7. Thermo Fisher Scientific Inc. 23.4.7.1. Overview 23.4.7.2. Product Portfolio 23.4.7.3. Key Financials 23.4.7.4. SWOT Analysis 23.4.7.5. Key Developments 23.4.7.6. Sales Footprint 23.4.7.7. Strategy Overview 23.4.7.7.1. Marketing Strategy 23.4.7.7.2. Product Strategy 23.4.7.7.3. Channel Strategy 23.4.8. Qiagen 23.4.8.1. Overview 23.4.8.2. Product Portfolio 23.4.8.3. Key Financials 23.4.8.4. SWOT Analysis 23.4.8.5. Key Developments 23.4.8.6. Sales Footprint 23.4.8.7. Strategy Overview 23.4.8.7.1. Marketing Strategy 23.4.8.7.2. Product Strategy 23.4.8.7.3. Channel Strategy 23.4.9. BIOMÉRIEUX 23.4.9.1. Overview 23.4.9.2. Product Portfolio 23.4.9.3. Key Financials 23.4.9.4. SWOT Analysis 23.4.9.5. Key Developments 23.4.9.6. Sales Footprint 23.4.9.7. Strategy Overview 23.4.9.7.1. Marketing Strategy 23.4.9.7.2. Product Strategy 23.4.9.7.3. Channel Strategy 23.4.10. Hologic Inc. 23.4.10.1. Overview 23.4.10.2. Product Portfolio 23.4.10.3. Key Financials 23.4.10.4. SWOT Analysis 23.4.10.5. Key Developments 23.4.10.6. Sales Footprint 23.4.10.7. Strategy Overview 23.4.10.7.1. Marketing Strategy 23.4.10.7.2. Product Strategy 23.4.10.7.3. Channel Strategy 23.4.11. Bio Rad Laboratories 23.4.11.1. Overview 23.4.11.2. Product Portfolio 23.4.11.3. Key Financials 23.4.11.4. SWOT Analysis 23.4.11.5. Key Developments 23.4.11.6. Sales Footprint 23.4.11.7. Strategy Overview 23.4.11.7.1. Marketing Strategy 23.4.11.7.2. Product Strategy 23.4.11.7.3. Channel Strategy 23.4.12. Quidel Corporation 23.4.12.1. Overview 23.4.12.2. Product Portfolio 23.4.12.3. Key Financials 23.4.12.4. SWOT Analysis 23.4.12.5. Key Developments 23.4.12.6. Sales Footprint 23.4.12.7. Strategy Overview 23.4.12.7.1. Marketing Strategy 23.4.12.7.2. Product Strategy 23.4.12.7.3. Channel Strategy 23.4.13. EKF Diagnostics 23.4.13.1. Overview 23.4.13.2. Product Portfolio 23.4.13.3. Key Financials 23.4.13.4. SWOT Analysis 23.4.13.5. Key Developments 23.4.13.6. Sales Footprint 23.4.13.7. Strategy Overview 23.4.13.7.1. Marketing Strategy 23.4.13.7.2. Product Strategy 23.4.13.7.3. Channel Strategy 23.4.14. SEKISUI Diagnostics 23.4.14.1. Overview 23.4.14.2. Product Portfolio 23.4.14.3. Key Financials 23.4.14.4. SWOT Analysis 23.4.14.5. Key Developments 23.4.14.6. Sales Footprint 23.4.14.7. Strategy Overview 23.4.14.7.1. Marketing Strategy 23.4.14.7.2. Product Strategy 23.4.14.7.3. Channel Strategy 23.4.15. DiaSys-Diagnostic Systems GmbH 23.4.15.1. Overview 23.4.15.2. Product Portfolio 23.4.15.3. Key Financials 23.4.15.4. SWOT Analysis 23.4.15.5. Key Developments 23.4.15.6. Sales Footprint 23.4.15.7. Strategy Overview 23.4.15.7.1. Marketing Strategy 23.4.15.7.2. Product Strategy 23.4.15.7.3. Channel Strategy 23.4.16. InBios International, Inc. 23.4.16.1. Overview 23.4.16.2. Product Portfolio 23.4.16.3. Key Financials 23.4.16.4. SWOT Analysis 23.4.16.5. Key Developments 23.4.16.6. Sales Footprint 23.4.16.7. Strategy Overview 23.4.16.7.1. Marketing Strategy 23.4.16.7.2. Product Strategy 23.4.16.7.3. Channel Strategy 23.4.17. Jiangsu Mole Bioscience Co., Ltd. 23.4.17.1. Overview 23.4.17.2. Product Portfolio 23.4.17.3. Key Financials 23.4.17.4. SWOT Analysis 23.4.17.5. Key Developments 23.4.17.6. Sales Footprint 23.4.17.7. Strategy Overview 23.4.17.7.1. Marketing Strategy 23.4.17.7.2. Product Strategy 23.4.17.7.3. Channel Strategy 23.4.18. ACON Laboratories, Inc. 23.4.18.1. Overview 23.4.18.2. Product Portfolio 23.4.18.3. Key Financials 23.4.18.4. SWOT Analysis 23.4.18.5. Key Developments 23.4.18.6. Sales Footprint 23.4.18.7. Strategy Overview 23.4.18.7.1. Marketing Strategy 23.4.18.7.2. Product Strategy 23.4.18.7.3. Channel Strategy 23.4.19. Visby Medical, Inc. 23.4.19.1. Overview 23.4.19.2. Product Portfolio 23.4.19.3. Key Financials 23.4.19.4. SWOT Analysis 23.4.19.5. Key Developments 23.4.19.6. Sales Footprint 23.4.19.7. Strategy Overview 23.4.19.7.1. Marketing Strategy 23.4.19.7.2. Product Strategy 23.4.19.7.3. Channel Strategy 23.4.20. UNIMA, INC. 23.4.20.1. Overview 23.4.20.2. Product Portfolio 23.4.20.3. Key Financials 23.4.20.4. SWOT Analysis 23.4.20.5. Key Developments 23.4.20.6. Sales Footprint 23.4.20.7. Strategy Overview 23.4.20.7.1. Marketing Strategy 23.4.20.7.2. Product Strategy 23.4.20.7.3. Channel Strategy 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Point-of-Care Diagnostics Market
